PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Guidelines : Allergic rhinitis
Guidelines : Allergic rhinitis
Additional Documents
Type
Document
Review Date
Other Drugs
- Fluticasone furoate
- Fluticasone with azelastine
- Cetirizine hydrochloride
- Loratadine
- Triamcinolone acetonide
- Beclometasone dipropionate
- Azelastine hydrochloride
- Desloratadine
- Levocetirizine
- Budesonide
- Mometasone furoate
- Ipratropium bromide
- Bilastine
- Mizolastine
- Acrivastine
- Fexofenadine hydrochloride
- Rupatadine fumarate
- House dust mites allergen extract
- White Birch pollen allergen extract
- Mometasone furoate with olopatadine
- Chlorphenamine maleate
- Ketotifen fumarate
- Promethazine hydrochloride
- Fluticasone propionate (Nasal)
Committee Recommendations
Date
Committee Name
Narrative
05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the Allergic Rhinitis guidance.
A GREEN traffic light status unless stated will be applied to all treatments within the guidance unless otherwise stated.
NON-FORMULARY traffic light status was agreed for the following treatments:
• Desloratadine and levocetirizine oral solutions
• Mizolastine
• Cetirizine capsules
• Rupatadine tablets
• Bilastine tablets
• Acrivastine capsules
BLUE (formerly Amber Star) traffic light status:
• Grazax (Gass Pollen extract) – this recommendation is under review